UNSPSC 51201516: Antilymphocyte or lymphocyte immune globulin

This classification denotes a serum containing gamma-globulins which are antibodies for lymphocyte antigens.

UNSPSC 51201516 Antilymphocyte or lymphocyte immune globulin is a Commodity code whose scope encompasses specialized immunoglobulin products used in clinical and therapeutic settings. Recent state and local procurement activity under this code shows limited volume; the single posted opportunity involves a vaccine product, suggesting potential misclassification or incidental tagging rather than core purchasing under the code's stated immunoglobulin scope. State and local issuers soliciting under this code include state health departments and related clinical procurement bodies. The work being bought reflects specialized pharmaceutical procurement where vendor qualification, regulatory clearance, and sole-source justification often drive purchasing decisions outside standard competitive bidding.

The Mississippi State Department of Health posted a sole source procurement notice for Yellow Fever Vaccine from Sanofi Pasteur, Inc. (Solicitation 3150006922, due August 3, 2026 at 10:00 a.m. CST) with objections to sole source classification due the same date. This notice announces a proposed sole source purchase with an objection period rather than a standard competitive RFP or IFB; any entity claiming an alternative vendor can supply the vaccine must submit written objection with supporting documentation to Cynthia Brasher at the Mississippi State Department of Health Purchasing Department by the deadline. If substantiated objections are received, the department will conduct an advertised competitive process; if it determines only Sanofi Pasteur can supply the product, it will appeal to the Public Procurement Review Board with burden of proof on the department. The notice does not disclose quantity, contract term, or estimated value. Recent activity under this code appears sparse and concentrated in state health department vaccine procurement rather than the broader antilymphocyte or lymphocyte immune globulin therapeutic market.